The kidney disease crescentic glomerulonephritis rapidly progresses to acute kidney failure and death within months if it is untreated. Even with treatment, many individuals buildup to end-stage kidney disease and require dialysis and sometimes a kidney transplant. New research in mice has identified a potential new drug target for the treatment of crescentic glomerulonephritis. In the study, mice lacking the mannose receptor protein were found to be protected from crescentic glomerulonephritis. This protection was correlated with decreased kidney damage mediated by cells known as macrophages and mesangial cells. Further, macrophages lacking the mannose receptor actually became antiinflammatory in the kidney after they interacted with mesangial cells. Researchers recommend that targeting the mannose receptor might provide a new approach to treating crescentic glomerulonephritis. Mainly, this path would not have the wide-ranging immunosuppressive effects that many current therapies have.